trending Market Intelligence /marketintelligence/en/news-insights/trending/PHWY2lh0M5SfpmTsRKGgNA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Windtree's heart failure drug gets US FDA fast-track status

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Windtree's heart failure drug gets US FDA fast-track status

The U.S. Food and Drug Administration granted fast-track designation to Windtree Therapeutics Inc.'s heart failure drug.

The Warrington, Pa.-based biotechnology company is developing istaroxime to treat symptoms of acute heart failure, a disease characterized by the sudden appearance or abrupt worsening of symptoms of heart failure.

Results from the company's phase 2 study showed that istaroxime improved cardiac function in patients with acute heart failure compared to placebo. The drug also maintained or increased blood pressure and decreased heart rate during the infusion in the mid-stage study.

The U.S. regulator grants fast-track designations to expedite the review of drugs that treat serious conditions and fill unmet medical needs. Incentives include frequent meetings and communications with the FDA and potential accelerated approval, priority review or rolling review.